Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.

@article{Held2015ClinicalOA,
  title={Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.},
  author={Claes Held and Elaine M. Hylek and John Hunter Alexander and Michael G. Hanna and Renato D Lopes and Daniel M. Wojdyla and Laine E Thomas and Hussein R. Al-Khalidi and Marco W Alings and Dennis Xavier and Jack Ansell and Shinichi Goto and Witold Ruźyllo and M{\aa}rten Rosenqvist and Freek W. A. Verheugt and Jun Zhu and Christopher B. Granger and Lars Wallentin},
  journal={European heart journal},
  year={2015},
  volume={36 20},
  pages={1264-72}
}
AIM In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of stroke, major bleed, and death in patients with atrial fibrillation. In this ancillary study, we evaluated clinical consequences of major bleeds, as well as management and treatment effects of warfarin vs. apixaban. METHODS AND RESULTS Major International Society on Thrombosis and Haemostasis bleeding was defined as overt… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS